Abu Dhabi has achieved a significant milestone by becoming the first location globally to administer ITVISMA™ (onasemnogene abeparvovec) for treating spinal muscular atrophy (SMA). This groundbreaking advancement not only underscores the emirate’s status as a premier healthcare destination but also highlights its dedication to patient care through innovations in genomics and precision medicine.
Accelerated Approval and Global Leadership
The UAE granted accelerated approval for ITVISMA™ on November 25, 2025, positioning it among the first countries, alongside the USA, to endorse this revolutionary treatment. This decision illustrates Abu Dhabi’s commitment to introducing leading-edge innovations that enhance healthcare accessibility for patients throughout the region. ITVISMA™ is designed to replace the missing SMN1 gene, thereby improving motor functions and reducing the necessity for ongoing treatments often required by other therapies.
Integrated Healthcare Ecosystem
Bader Al Qubaisi, Chief Executive Officer at Sheikh Khalifa Medical City (SKMC), emphasized that the administration of ITVISMA™ is a testament to Abu Dhabi’s integrated healthcare ecosystem. Under the guidance of the Department of Health – Abu Dhabi, the collaboration with partners, including Novartis, has made it possible to deliver this transformative therapy to patients in a safe and efficient manner.
Focus on Patients and Families
“The true significance of this milestone lies in its impact on patients and their families,” stated Mohamed Ezz Eldin, Head of the GCC Cluster at Novartis. Emphasizing the collaborative efforts with the Department of Health – Abu Dhabi and SKMC, he expressed pride in supporting expedited access to breakthrough therapies like ITVISMA™. This collaboration further solidifies Abu Dhabi’s emerging role as a hub for advanced neuromuscular care on both regional and global scales.
Implications for Precision Medicine
The introduction of ITVISMA™ represents a paradigm shift in the treatment of SMA. By addressing the root cause of the disease through gene replacement, this therapy holds the potential for long-term benefits that can improve the quality of life for patients. It marks a significant advancement in the field of precision medicine, where therapies are tailored to individual genetic profiles, paving the way for more effective treatments.
Future Prospects in Healthcare
As Abu Dhabi continues to innovate and expand its healthcare capabilities, the successful implementation of ITVISMA™ could inspire further research and development in gene therapies. This achievement may set a precedent for other regions aiming to enhance their healthcare systems by incorporating cutting-edge technologies and treatments.
Key Takeaways
- Abu Dhabi is the first city worldwide to offer ITVISMA™ for spinal muscular atrophy treatment.
- The UAE’s accelerated approval of this therapy highlights its leadership in global healthcare.
-
ITVISMA™ replaces the missing SMN1 gene, potentially reducing the need for continuous treatment.
-
Collaboration between healthcare providers and pharmaceutical companies fosters rapid access to innovative therapies.
-
This milestone enhances Abu Dhabi’s reputation as a center for advanced neuromuscular care.
In conclusion, Abu Dhabi’s introduction of ITVISMA™ signifies a remarkable achievement in the realm of healthcare, blending innovation with a patient-centered approach. This landmark treatment not only reflects the emirate’s dedication to advanced medical care but also sets a new standard for future healthcare initiatives. The journey towards improved patient outcomes through precision medicine has only just begun.
Read more → www.doh.gov.ae